Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Clin Adv Hematol Oncol. 2016 Jul;14(7):543-54
Authors: Varma G, Johnson TP, Advani RH
Abstract
The development of Bruton's tyrosine kinase (BTK) inhibitors and their introduction into clinical practice represent a major advance in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. Although ibrutinib is the only BTK inhibitor that has been approved by the US Food and Drug Administration, several others are under investigation. Ibrutinib is currently approved for use in relapsed/refractory CLL, CLL with 17p deletion (del[17p]), relapsed or refractory mantle cell lymphoma, and Waldenström macroglobulinemia. Although it is clear that ibrutinib has altered treatment paradigms and outcomes in these diseases, several questions remain regarding (1) its role in frontline vs salvage therapy; (2) its use as a single agent vs in combination with biologic agents, other small molecules, or traditional chemoimmunotherapy; (3) the optimal duration of treatment; and (4) the treatment of patients who cannot tolerate or have disease resistant to ibrutinib. Because sparse clinical data are available on other BTK inhibitors, it is unclear at present whether their clinical efficacy and toxicity will differ from those of ibrutinib.
PMID: 27379948 [PubMed - in process]

Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research